BR112022021905A2 - Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo - Google Patents
Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmoInfo
- Publication number
- BR112022021905A2 BR112022021905A2 BR112022021905A BR112022021905A BR112022021905A2 BR 112022021905 A2 BR112022021905 A2 BR 112022021905A2 BR 112022021905 A BR112022021905 A BR 112022021905A BR 112022021905 A BR112022021905 A BR 112022021905A BR 112022021905 A2 BR112022021905 A2 BR 112022021905A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- polynucleotide
- suffered
- polypeptide
- vector
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000008904 Betacoronavirus Species 0.000 title abstract 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202070282 | 2020-05-01 | ||
| DKPA202070293 | 2020-05-06 | ||
| DKPA202070735 | 2020-11-05 | ||
| DKPA202070820 | 2020-12-08 | ||
| DKPA202170069 | 2021-02-15 | ||
| PCT/EP2021/061602 WO2021219897A1 (en) | 2020-05-01 | 2021-05-03 | Betacoronavirus prophylaxis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021905A2 true BR112022021905A2 (pt) | 2022-12-13 |
Family
ID=75870604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021905A BR112022021905A2 (pt) | 2020-05-01 | 2021-05-03 | Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230165952A1 (https=) |
| EP (1) | EP4143210A1 (https=) |
| JP (1) | JP2023524054A (https=) |
| KR (1) | KR20230005962A (https=) |
| CN (1) | CN116096735A (https=) |
| AU (1) | AU2021262521A1 (https=) |
| BR (1) | BR112022021905A2 (https=) |
| CA (1) | CA3176527A1 (https=) |
| IL (1) | IL297621A (https=) |
| MX (1) | MX2022013661A (https=) |
| WO (1) | WO2021219897A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| US12384811B2 (en) | 2019-04-05 | 2025-08-12 | Academia Sinica | Sialidase-resistant saccharide and method of making and using the same |
| CN112028978B (zh) * | 2020-09-07 | 2023-06-16 | 重庆医科大学 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
| BR112023000666A2 (pt) | 2021-04-12 | 2023-10-24 | Academia Sinica | Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica |
| BR112023023260A2 (pt) | 2021-05-10 | 2024-01-30 | Nykode Therapeutics ASA | Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica |
| JP2024518463A (ja) | 2021-05-10 | 2024-05-01 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | 構築物及び免疫阻害化合物の共発現 |
| TW202334429A (zh) * | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| CN113801209B (zh) * | 2021-11-16 | 2022-02-11 | 浙江普康生物技术股份有限公司 | 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法 |
| GB202201765D0 (en) * | 2022-02-11 | 2022-03-30 | Virax Biolabs Uk Ltd | Methods |
| CN114832099B (zh) * | 2022-04-08 | 2023-11-28 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂 |
| CN114907452B (zh) * | 2022-04-08 | 2023-07-25 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 |
| US20260007729A1 (en) * | 2022-08-17 | 2026-01-08 | IMMUNEO Therapeutics GmbH | Immunization against viral infections disease(s) |
| WO2024038157A1 (en) * | 2022-08-17 | 2024-02-22 | PMCR GmbH | Immunization against coronavirus |
| LU102995B1 (en) * | 2022-08-17 | 2024-02-19 | PMCR GmbH | Immunization against coronavirus |
| WO2024044747A2 (en) * | 2022-08-25 | 2024-02-29 | University Of Florida Research Foundation, Inc. | Immunogenic composition and uses thereof |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
| WO2024155907A2 (en) * | 2023-01-20 | 2024-07-25 | Duke University | Epitope-scaffold immunogens for pancoronavirus vaccines |
| WO2024210175A1 (ja) * | 2023-04-07 | 2024-10-10 | 国立大学法人大阪大学 | 濾胞性ヘルパーＴ細胞誘導性ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質の部分ペプチド |
| AU2024252371B2 (en) | 2023-04-08 | 2026-02-12 | Rock Biomedical Inc. | Methods and compositions for dendritic cell targeting nano-delivery |
| US12318485B2 (en) | 2023-04-08 | 2025-06-03 | Rock Biomedical, Inc. | Methods and compositions for targeted delivery by polymersomes |
| WO2024238734A2 (en) | 2023-05-17 | 2024-11-21 | Rock Biomedical Inc. | Mgat1 deficient cells and uses thereof |
| CN119143850A (zh) * | 2024-08-20 | 2024-12-17 | 复旦大学 | 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531204T3 (es) | 2003-02-25 | 2015-03-11 | Vaccibody As | Anticuerpo modificado |
| JP2013532971A (ja) * | 2010-06-25 | 2013-08-22 | バッシボディ アクスイェ セルスカプ | ホモ二量体タンパク質コンストラクト |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| BR112014015016B1 (pt) | 2011-12-21 | 2023-10-03 | Nykode Therapeutics ASA | Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina |
| IL260030B2 (en) * | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| EP3678699A1 (en) * | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
| WO2020176797A1 (en) | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| LT3972987T (lt) * | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
| WO2021216954A1 (en) * | 2020-04-23 | 2021-10-28 | Alpha Beta Holdings, Llc | Compositions and methods for treating or preventing virus infection |
-
2021
- 2021-05-03 KR KR1020227042131A patent/KR20230005962A/ko active Pending
- 2021-05-03 MX MX2022013661A patent/MX2022013661A/es unknown
- 2021-05-03 AU AU2021262521A patent/AU2021262521A1/en active Pending
- 2021-05-03 JP JP2022566176A patent/JP2023524054A/ja active Pending
- 2021-05-03 US US17/997,407 patent/US20230165952A1/en active Pending
- 2021-05-03 WO PCT/EP2021/061602 patent/WO2021219897A1/en not_active Ceased
- 2021-05-03 CN CN202180032441.8A patent/CN116096735A/zh active Pending
- 2021-05-03 BR BR112022021905A patent/BR112022021905A2/pt unknown
- 2021-05-03 CA CA3176527A patent/CA3176527A1/en active Pending
- 2021-05-03 EP EP21724230.4A patent/EP4143210A1/en active Pending
- 2021-05-03 IL IL297621A patent/IL297621A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021262521A1 (en) | 2022-12-08 |
| KR20230005962A (ko) | 2023-01-10 |
| CA3176527A1 (en) | 2021-11-04 |
| IL297621A (en) | 2022-12-01 |
| WO2021219897A1 (en) | 2021-11-04 |
| CN116096735A (zh) | 2023-05-09 |
| JP2023524054A (ja) | 2023-06-08 |
| MX2022013661A (es) | 2022-11-30 |
| US20230165952A1 (en) | 2023-06-01 |
| EP4143210A1 (en) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021905A2 (pt) | Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo | |
| Monschein et al. | Vaccination and multiple sclerosis in the era of the COVID-19 pandemic | |
| Treanor et al. | Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+ GLA) adjuvant | |
| Levin et al. | Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same? | |
| Goff et al. | Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies | |
| BR112022014808A2 (pt) | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 | |
| BR112022013573A2 (pt) | Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre grupos | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| Pedrazzoli et al. | Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM) | |
| Jamshed et al. | Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial | |
| BR112018074152A8 (pt) | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
| EA202091563A1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа | |
| Camilloni et al. | Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A (H3N2) strains | |
| Triglav et al. | Vaccination indications and limits in the elderly | |
| Arakane et al. | Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study | |
| Arakane et al. | Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial | |
| BR112023016241A2 (pt) | Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos | |
| Rangappa | Cytokine storm and immunomodulation in COVID-19 | |
| BR112016012435A8 (pt) | vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 | |
| Lei et al. | Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets | |
| BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular |